Comprehensive 2025 Focal Segmental Glomerulosclerosis Market Overview: Trends, Forecasts, and Growth Drivers

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Focal Segmental Glomerulosclerosis Market Through 2025?
In recent times, notable expansion has been observed in the focal segmental glomerulosclerosis market. There is an anticipated growth from $1.46 billion in 2024 to $1.57 billion in 2025, experiencing a compound annual growth rate (CAGR) of 7.6%. This growth over the historic period can be traced back to factors such as the escalating prevalence of chronic kidney diseases, heightened awareness about kidney disorders, an increase in incidents of end-stage renal disease, generous investment in research and development, and a rise in the elderly population.

What's the Projected Size of the Global Focal Segmental Glomerulosclerosis Market by 2029?
The market size for focal segmental glomerulosclerosis is set to witness robust expansion in the upcoming years. Projected to rise to $2.09 billion in 2029, at a compound annual growth rate (CAGR) of 7.3%, this growth in the forecast period can be credited to an increase in clinical trials, enhancements in healare infrastructure, a surge in the demand for personalized medicine, greater accessibility of immunosuppressive drugs and a spike in the need for custom therapeutic interventions. Key trends during the forecast period include breakthroughs in genetic research, incorporation of precision medicine, technological advancements in diagnostic tools, progress in the formulation of immunosuppressive drugs, and strides made in identifying biomarkers.

View the full report here:
https://www.thebusinessresearchcompany.com/report/focal-segmental-glomerulosclerosis-global-market-report

Top Growth Drivers in the Focal Segmental Glomerulosclerosis Industry: What's Accelerating the Market?
The growth of the focal segmental glomerulosclerosis market is likely to be driven by the increasing incidence of kidney disorders. Such pathological conditions involve structural and functional impairment of the kidneys, compromising their ability to eliminate waste, maintain fluid balance, and perform other vital body functions. A significant contributor to the high prevalence of kidney disorders is diabetes because it damages the kidneys' filtration systems over a period, resulting in diabetic nephropathy. Focal segmental glomerulosclerosis underlines the gradual scarring of kidney filters, becoming an essential signpost and focus in understanding, diagnosing, and treating chronic kidney conditions. For example, the Australian Institute of Health and Welfare released data in December 2024 showing that mortality rates due to chronic kidney disease (CKD) had increased in succession in both 2021 and 2022, with a rise of 4.2% and 6.2% respectively. Consequently, the escalating incidence of kidney-related diseases is stimulating the growth of the focal segmental glomerulosclerosis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24541&type=smp

What Trends Will Shape the Focal Segmental Glomerulosclerosis Market Through 2029 and Beyond?
Firms at the forefront of the focal segmental glomerulosclerosis market are emphasizing the creation of groundbreaking therapies like non-immunosuppressive oral medicine to enhance patient health and mitigate treatment side effects. Non-immunosuppressive oral medicine is an orally-consumed drug that manages illness without impairing the immune system, effectively handling focal segmental glomerulosclerosis by directly targeting kidney damage and avoiding immune-related complications. For example, in May 2025, U.S-based biopharmaceutical firm, Travere Therapeutics Inc., obtained approval from the U.S. Food and Drug Administration (FDA) for their al New Drug Application (sNDA) for FILSPARI (sparsentan), earning standard approval for the treatment of focal segmental glomerulosclerosis (FSGS). FILSPARI, a pioneering therapy, operates by concurrently blocking both the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This double action markedly decreases proteinuria in cases like FSGS and IgA nephropathy. FILSPARI, compared to current treatments, provides superior kidney defence while preserving a robust safety record.

What Are the Main Segments in the Focal Segmental Glomerulosclerosis Market?
The focal segmental glomerulosclerosis market covered in this report is segmented -

1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis
2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments
3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids
4) By Route Of Administration: Oral, Parenteral
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant
2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24541&type=smp

Which Top Companies are Driving Growth in the Focal Segmental Glomerulosclerosis Market?
Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.

Which Regions Will Dominate the Focal Segmental Glomerulosclerosis Market Through 2029?
North America was the largest region in the focal segmental glomerulosclerosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the focal segmental glomerulosclerosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24541

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.